The potential of Zn(II) N-alkylpyridylporphyrins for anticancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 2, 2011, Pages 233-241

  Benov, Ludmil ^a   Craik, James ^a   Batinic Haberle, Ines ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Meta and para isomeric Zn(II) N alkylpyridylporphyrins; Ortho; Photodynamic therapy; Photosensitizer; Singlet oxygen

Indexed keywords

ALKYL GROUP; ANTINEOPLASTIC AGENT; PORPHYRIN DERIVATIVE; PYRIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SINGLET OXYGEN; ZINC DERIVATIVE;

ANTIOXIDANT ACTIVITY; CANCER CELL; CELL DAMAGE; CHELATION; IRRADIATION; OXIDATION REDUCTION REACTION; PHOTOSENSITIZATION; REVIEW;

EID: 79953797299     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152011795255975     Document Type: Review

References (112)

1. Burhans, W. C.; Heintz, N. H. The cell cycle is a redox cycle: Linking phase-specific targets to cell fate. Free Radic. Biol. Med., 2009, 47, 1282-1293.
2. Grek, C. L.; Tew, K. D. Redox metabolism and malignancy. Curr. Opin. Pharmacol., 2010, 10, 362-368.
3. Forman, H. J.; Maiorino, M.; Ursini, F. Signaling functions of reactive oxygen species. Biochemistry, 2010, 49, 835-842.
4. Halliwell, B.; Gutteridge, J. M. C. Free Radicals in Biology and Medicine; Third ed.; Oxford University Press: Oxford, New York, 1999.
5. Matés, J. M.; Sánchez-Jiménez, F. M. Role of reactive oxygen species in apoptosis: Implications for cancer therapy. Internat. J. Biochem. Cell Biol., 2000, 32, 157-170.
6. Manda, G.; Nechifor, M. T.; Neagu, T.-M. Reactive oxygen species, cancer and anti-cancer therapies. Curr. Chem. Biol., 2009, 3, 22-46.
7. Wang, J.; Yi, J. Cancer cell killing via ROS: To increase or decrease, that is a question. Cancer Biol. Ther., 2008, 7, 1875-1884.
8. Brigelius-Flohé, R.; Kipp, A. Glutathione peroxidases in different stages of carcinogenesis. Biochim. Biophys. Acta, 2009, 1790, 1555-1568.
9. Kinnula, V. L.; Crapo, J. D. Superoxide dismutases in malignant cells and human tumors. Free Radic. Biol. Med., 2004, 36, 718-744.
10. Oberley, L. W. Anticancer therapy by overexpression of superoxide dismutase. Antiox. Redox Sig., 2001, 3, 461-472.
11. Verrax, J.; Pedrosa, R. C.; Beck, R.; Dejeans, N.; Taper, H.; Calderon, P. B. In situ modulation of oxidative stress: A novel and efficient strategy to kill cancer cells. Curr. Med. Chem., 2009, 16, 1821-1830.
12. Fang, J.; Seki, T.; Maeda, H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev., 2009, 61, 290-302.
13. Frank, J.; Kelleher, D. K.; Pompella, A.; Thews, O.; Biesalski, H. K.; Vaupel, P. Enhancement of oxidative cell injury and antitumor effects of localized 44°C hyperthermia upon combination with respiratory hyperoxia and xanthine oxidase. Cancer Res., 1998, 58, 2693-2698.
14. Sawa, T.; Wu, J.; Akaike, T.; Maeda, H. Enhanced tumor targeting and antitumor activity of xanthine oxidase by chemical conjugation with PEG. Proc. Contr. Rel. Soc., 1998, 12-13.
15. Sawa, T.; Wu, J.; Akaike, T.; Maeda, H. Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue. Cancer Res., 2000, 60, 666-671.
16. Vaupel, P.; Kelleher, D. K.; Thews, O.; Pompella, A.; Biesalski, H. K.; Frank, J. Xanthine oxidase and respiratory hyperoxia enhance the antitumor effect of localized 44°C hyperthermia. FASEB J., 1998, 12.
17. Ben-Yoseph, O.; Ross, B. D. Oxidation therapy: The use of a reactive oxygen species-generating enzyme system for tumour treatment. Br. J. Cancer, 1994, 70, 1131-1135.
18. Yoshikawa, T.; Kokura, S.; Tainaka, K.; Naito, Y.; Kondo, M. A novel cancer therapy based on oxygen radicals. Cancer Res., 1995, 55, 1617-1620.
19. Ralph, S. J. Arsenic-based antineoplastic drugs and their mechanisms of action. Metal-Based Drugs 2008, 2008, Article ID 260146, doi:260110.261155/262008/260146.
20. Hill, D. L.; Montgomery, J. A. Selective uptake and retention of anticancer agents by sensitive cells. Cancer Chemother. Pharmacol., 1980, 4, 221-225.
21. Tian, J.; Peehl, D. M.; Knox, S. J. Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through fenton chemistry. Cancer Biother. Radiopharm., 2010, 25, 439-448.
22. Waibel, R.; Treichler, H.; Schaefer, N. G.; Van Staveren, D. R.; Mundwiler, S.; Kunze, S.; Küenzi, M.; Alberto, R.; Nüesch, J.; Knuth, A.; Moch, H.; Schibli, R.; Schubiger, P. A. New derivatives of vitamin B12 show preferential targeting of tumors. Cancer Res., 2008, 68, 2904-2911.
23. Moan, J.; Berg, K. Photochemotherapy of cancer: experimental research. Photochem. Photobiol., 1992, 55, 931-948.
24. Henderson, B. W.; Dougherty, T. J. How does photodynamic therapy work? Photochem. Photobiol., 1992, 55, 145-157.
25. Nyman, E. S.; Hynninen, P. H. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B, 2004, 73, 1-28.
26. Dougherty, T. J.; Gomer, C. J.; Henderson, B. W.; Jori, G.; Kessel, D.; Korbelik, M.; Moan, J.; Peng, Q. Photodynamic therapy. J. Natl. Cancer Inst., 1998, 90, 889-905.
27. Villanueva, A.; Caggiari, L.; Jori, G.; Milanesi, C. Morphological aspects of an experimental tumour photosensitized with a mesosubstituted cationic porphyrin. J. Photochem. Photobiol. B, 1994, 23, 49-56.
28. Spasojević, I.; Kos, I.; Benov, L. T.; Rajic, Z.; Fels, D.; Dedeugd, C.; Ye, X.; Vujaskovic, Z.; Reboucas, J. S.; Leong, K. W.; Dewhirst, M. W.; Batinic-Haberle, I. Bioavailability of metalloporphyrin-based SOD mimics is greatly influenced by a single charge residing on a Mn site. Free Radic. Res., 2011, 45, 188-200.
29. Ye, X.; Fels, D.; Dedeugd, C.; Dewhirst, M. W.; Leong, K.; Batinic-Haberle, I. The in vitro cytotoxic effects of Mn(III) alkylpyridylporphyrin/ascorbate system on four tumor cell lines. Free Radic. Biol. Med., 2009, 47, S136.
30. Batinic-Haberle, I.; Rajic, Z.; Benov, L. A combination of two antioxidants (an SOD mimic and ascorbate) produces a prooxidative effect forcing Escherichia coli to adapt via induction of oxyR regulon. Anticancer Agents Med. Chem., 2011, this Issue, in press.
31. Wainwright, M. Photodynamic therapy: The development of new photosensitisers. Anticancer Agents Med. Chem., 2008, 8, 280-291.
32. Davies, M. J. Reactive species formed on proteins exposed to singlet oxygen. Photochem. Photobiol. Sci., 2004, 3, 17-25.
33. Ogilby, P. R. Singlet oxygen: There is indeed something new under the sun. Chem. Soc. Rev., 2010, 39, 3181-3209.
34. Moan, J. On the diffusion length of singlet oxygen in cells and tissues. J. Photochem. Photobiol. B, 1990, 6, 343-344.
35. Moan, J.; Berg, K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem. Photobiol., 1991, 53, 549-553.
36. Rubio, N.; Fleury, S. P.; Redmond, R. W. Spatial and temporal dynamics of in vitro photodynamic cell killing: Extracellular hydrogen peroxide mediates neighbouring cell death. Photochem. Photobiol. Sci., 2009, 8, 457-464.
37. Redmond, R. W.; Kochevar, I. E. Spatially resolved cellular responses to singlet oxygen. Photochem. Photobiol., 2006, 82, 1178-1186.
38. MacDonald, I. J.; Morgan, J.; Bellnier, D. A.; Paszkiewicz, G. M.; Whitaker, J. E.; Litchfield, D. J.; Dougherty, T. J. Subcellular localization patterns and their relationship to photodynamic activity of pyropheophorbide-a derivatives. Photochem. Photobiol., 1999, 70, 789-797.
39. Gollnick, S.; Henderson, B. W. In CRC Handbookof Organic Photochemistry and Photobiology; Horspool, W., Lenci, F. Ed.; CRC Press: Boca Raton, 2003; pp, 1-25.
40. Henderson, B. W.; Bellnier, D. A.; Greco, W. R.; Sharma, A.; Pandey, R. K.; Vaughan, L. A.; Weishaupt, K. R.; Dougherty, T. J. An in vivo quantitative structure-activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitizers for photodynamic therapy. Cancer Res., 1997, 57, 4000-4007.
41. Ball, D. J.; Mayhew, S.; Wood, S. R.; Griffiths, J.; Vernon, D. I.; Brown, S. B. A comparative study of the cellular uptake and photodynamic efficacy of three novel zinc phthalocyanines of differing charge. Photochem. Photobiol., 1999, 69, 390-396.
42. Hamblin, M. R.; Hasan, T. Photodynamic therapy: A new antimicrobial approach to infectious disease? Photochem. Photobiol. Sci., 2004, 3, 436-450.
43. Mroz, P.; Bhaumik, J.; Dogutan, D. K.; Aly, Z.; Kamal, Z.; Khalid, L.; Kee, H. L.; Bocian, D. F.; Holten, D.; Lindsey, J. S.; Hamblin, M. R. Imidazole metalloporphyrins as photosensitizers for photodynamic therapy: Role of molecular charge, central metal and hydroxyl radical production. Cancer Lett., 2009, 282, 63-76.
44. Benov, L.; Batinic-Haberle, I.; Spasojevic, I.; Fridovich, I. Isomeric N-alkylpyridylporphyrins and their Zn(II) complexes: inactive as SOD mimics but powerful photosensitizers. Arch. Biochem. Biophys., 2002, 402, 159-165.
45. Kalyanasundaram, K. Photochemistry of water-soluble porphyrins: Comparative study of Isomeric Tetrapyridyl-and tetrakis(NMethylpyridiniumyl) porphyrins. Inorg. Chem., 1983, 23, 2453-2459.
46. Pavani, C.; Uchoa, A. F.; Oliveira, C. S.; Iamamoto, Y.; Baptista, M. S. Effect of zinc insertion and hydrophobicity on the membrane interactions and PDT activity of porphyrin photosensitizers. Photochem. Photobiol. Sci., 2009, 8, 233-240.
47. Juzeniene, A.; Moan, J. The history of PDT in Norway. Part one: Identification of basic mechanisms of general PDT. Photodiag. Photodyn. Ther., 2007, 4, 3-11.
48. Boyle, R. W.; Dolphin, D. Structure and biodistribution relationships of photodynamic sensitizers. Photochem. Photobiol., 1996, 64, 469-485.
49. Castano, A. P.; Demidova, T. N.; Hamblin, M. R. Mechanisms in photodynamic therapy: Part one-Photosensitizers, photochemistry and cellular localization. Photodiag. Photodyn. Ther., 2004, 1, 279-293.
50. Jensen, T. J.; Vicente, M. G. H.; Luguya, R.; Norton, J.; Fronczek, F. R.; Smith, K. M. Effect of overall charge and charge distribution on cellular uptake, distribution and phototoxicity of cationic porphyrins in HEp2 cells. J. Photochem. Photobiol. B, 2010, 100, 100-111.
51. Engelmann, F. M.; Mayer, I.; Gabrielli, D. S.; Toma, H. E.; Kowaltowski, A. J.; Araki, K.; Baptista, M. S. Interaction of cationic meso-porphyrins with liposomes, mitochondria and erythrocytes. J. Bioenerg. Biomem., 2007, 39, 175-185.
52. Kessel, D. Correlation between subcellular localization and photodynamic efficacy. J. Porph. Phthaloc., 2004, 8, 1009-1014.
53. Kessel, D.; Luo, Y.; Deng, Y.; Chang, C. K. The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem. Photobiol., 1997, 65, 422-426.
54. Kessel, D.; Woodburn, K.; Henderson, B. W.; Chang, C. K. Sites of photodamage in vivo and in vitro by a cationic porphyrin. Photochem. Photobiol., 1995, 62, 875-881.
55. Kessel, D.; Luguya, R.; Vicente, M. G. H. Localization and Photodynamic Efficacy of Two Cationic Porphyrins Varying in Charge Distribution. Photochem. Photobiol., 2003, 78, 431-435.
56. Sibrian-Vazquez, M.; Nesterova, I. V.; Jensen, T. J.; Vicente, M. G. H. Mitochondria targeting by guanidine-and biguanidineporphyrin photosensitizers. Bioconj. Chem., 2008, 19, 705-713.
57. Ricchelli, F.; Franchi, L.; Miotto, G.; Borsetto, L.; Gobbo, S.; Nikolov, P.; Bommer, J. C.; Reddi, E. Meso-substituted tetracationic porphyrins photosensitize the death of human fibrosarcoma cells via lysosomal targeting. Int. J. Biochem. Cell Biol., 2005, 37, 306-319.
58. Sibrian-Vazquez, M.; Jensen, T. J.; Fronczek, F. R.; Hammer, R. P.; Vicente, M. G. H. Synthesis and characterization of positively charged porphyrin-pep tide conjugates. Bioconj. Chem., 2005, 16, 852-863.
59. Al-Mutairi, D. A.; Craik, J. D.; Batinic-Haberle, I.; Benov, L. T. Photosensitizing action of isomeric zinc N-methylpyridyl porphyrins in human carcinoma cells. Free Rad. Res., 2006, 40, 477-483.
60. Al-Mutairi, D. A.; Craik, J. D.; Batinic-Haberle, I.; Benov, L. T. Induction of oxidative cell damage by photo-treatment with zinc Nmethylpyridylporphyrin. Free Rad. Res., 2007, 41, 89-96.
61. Dewhirst, M. W.; Cao, Y.; Moeller, B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Rev. Cancer, 2008, 8, 425-437.
62. Cárdenas-Navia, L. I.; Mace, D.; Richardson, R. A.; Wilson, D. F.; Shan, S.; Dewhirst, M. W. The pervasive presence of fluctuating oxygenation in tumors. Cancer Res., 2008, 68, 5812-5819.
63. Agon, V. V.; Bubb, W. A.; Wright, A.; Hawkins, C. L.; Davies, M. J. Sensitizer-mediated photooxidation of histidine residues: Evidence for the formation of reactive side-chain peroxides. Free Radic. Biol. Med., 2006, 40, 698-710.
64. Ngen, E. J.; Rajaputra, P.; You, Y. Evaluation of delocalized lipophilic cationic dyes as delivery vehicles for photosensitizers to mitochondria. Bioorg. Med. Chem., 2009, 17, 6631-6640.
65. Morgan, J.; Oseroff, A. R. Mitochondria-based photodynamic anticancer therapy. Adv. Drug Deliv. Rev., 2001, 49, 71-86.
66. Dummin, H.; Cernay, T.; Zimmermann, H. W. Selective photosensitization of mitochondria in HeLa cells by cationic Zn(II)phthalocyanines with lipophilic side-chains. J. Photochem. Photobiol. B, 1997, 37, 219-229.
67. Murphy, M. P.; Smith, R. A. J. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Ann. Rev. Pharmacol. Toxicol., 2007, 47, 629-656.
68. Hoye, A. T.; Davoren, J. E.; Wipf, P.; Fink, M. P.; Kagan, V. E. Targeting mitochondria. Acc. Chem. Res., 2008, 41, 87-97.
69. Kos, I.; Benov, L.; Spasojevic, I.; Reboucas, J. S.; Batinic-Haberle, I. High lipophilicity of meta Mn(III) N-alkylpyridylporphyrinbased superoxide dismutase mimics compensates for their lower antioxidant potency and makes them as effective as ortho analogues in protecting superoxide dismutase-deficient Escherichia coli. J. Med. Chem., 2009, 52, 7868-7872.
70. Spasojevic, I.; Chen, Y.; Noel, T. J.; Yu, Y.; Cole, M. P.; Zhang, L.; Zhao, Y.; St. Clair, D. K.; Batinic-Haberle, I. Mn porphyrinbased superoxide dismutase (SOD) mimic, MnIIITE-2-PyP5+, targets mouse heart mitochondria. Free Radic. Biol. Med., 2007, 42, 1193-1200.
71. Spasojević, I.; Li, A. M.; Tovmasyan, A.; Rajic, Z.; Salvemini, D.; St. Clair, D.; Valentine, J. S.; Vujaskovic, Z.; Gralla, E. B.; Batinic-Haberle, I. Accumulation of porphyrin-based SOD mimics in mitochondria is proportional to their lipophilicity. S. cerevisiae study of ortho Mn(III) N-alkylpyridylporphyrins Free Radic. Biol. Med., 2010, 49, S199.
72. Al-Mutairi, D. A.; Craik, J. D.; Batinic-Haberle, I.; Benov, L. T. Inactivation of metabolic enzymes by photo-treatment with zinc meta N-methylpyridylporphyrin. Biochim. Biophys. Acta, 2007, 1770, 1520-1527.
73. Hilf, R. Mitochondria are targets of photodynamic therapy. J. Bioenerget. Biomembr., 2007, 39, 85-89.
74. Hilf, R.; Warne, N. W.; Smail, D. B.; Gibson, S. L. Photodynamic inactivation of selected intracellular enzymes by hematoporphyrin derivative and their relationship to tumor cell viability in vitro. Cancer Lett., 1984, 24, 165-172.
75. Atlante, A.; Passarella, S.; Quagliariello, E.; Moreno, G.; Salet, C. Haematoporphyrin derivative (Photofrin II) photosensitization of isolated mitochondria: inhibition of ADP/ATP translocator. J. Photochem. Photobiol. B, 1989, 4, 35-46.
76. Salet, C.; Moreno, G. Photodynamic action increases leakage of the mitochondrial electron transport chain. Int. J. Radiat. Biol., 1995, 67, 477-480.
77. Coppola, A.; Viggiani, E.; Salzarulo, L.; Rasile, G. Ultrastructural changes in lymphoma cells treated with hematoporphyrin and light. Am J Pathol 1980, 99, 175-192.
78. Kessel, D. Relocalization of cationic porphyrins during photodynamic therapy. Photochem. Photobiol. Sci., 2002, 1, 837-840.
79. Alvarez, M.; Villanueva, A.; Acedo, P.; Cañete, M.; Stockert, J. C. Cell death causes relocalization of photosensitizing fluorescent probes. Acta Histochem., 2010, in press.
80. Kessel, D.; Conley, M.; Vicente, M. G. H.; Reiners Jr, J. J. Studies on the subcellular localization of the porphycene CPO. Photochem. Photobiol., 2005, 81, 569-572.
81. Teiten, M. H.; Marchal, S.; D'Hallewin, M. A.; Guillemin, F.; Bezdetnaya, L. Primary Photodamage Sites and Mitochondrial Events after Foscan® Photosensitization of MCF-7 Human Breast Cancer Cells. Photochem. Photobiol., 2003, 78, 9-14.
82. Agostinis, P.; Assefa, Z.; Vantieghem, A.; Vandenheede, J. R.; Merlevede, W.; De Witte, P. Apoptotic and anti-apoptotic signaling pathways induced by photodynamic therapy with hypericin. Adv. Enzyme Regul., 2000, 40, 157-182.
83. Matroule, J. Y.; Carthy, C. M.; Granville, D. J.; Jolois, O.; Hunt, D. W. C.; Piette, J. Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization. Oncogene, 2001, 20, 4070-4084.
84. Kessel, D.; Luo, Y. Photodynamic therapy: A mitochondrial inducer of apoptosis. Cell Death Diff., 1999, 6, 28-35.
85. Moor, A. C. E. Signaling pathways in cell death and survival after photodynamic therapy. J. Photochem. Photobiol. B, 2000, 57, 1-13.
86. Oleinick, N. L.; Morris, R. L.; Belichenko, I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem. Photobiol. Sci., 2002, 1, 1-21.
87. Patito, I. A.; Rothmann, C.; Malik, Z. Nuclear transport of photosensitizers during photosensitization and oxidative stress. Biol. Cell, 2001, 93, 285-291.
88. Berg, K.; Moan, J. Lysosomes and microtubules as targets for photochemotherapy of cancer. Photochem. Photobiol., 1997, 65, 403-409.
89. Fuchs, J.; Weber, S.; Kaufmann, R. Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: Implications for clinical photodynamic therapy. Free Radic. Biol. Med., 2000, 28, 537-548.
90. Ruck, A.; Kollner, T.; Dietrich, A.; Strauss, W.; Schnekcenburger, H. Fluorescence formation during photodynamic therapy in the nucleus of cells incubated with cationic and anionc water-soluble photosensitizers. J. Photochem. Photobiol. B, 1992, 12, 403-412.
91. Snyder, J. W.; Lambert, J. D. C.; Ogilby, P. R. 5,10,15,20-Tetrakis(N-methyl-4-pyridyl)-21H,23H-porphine (TMPyP) as a sensitizer for singlet oxygen imaging in cells: Characterizing the irradiation-dependent behavior of TMPyP in a single cell. Photochem. Photobiol., 2006, 82, 177-184.
92. Skovsen, E.; Snyder, J. W.; Lambert, J. D. C.; Ogilby, P. R. Lifetime and diffusion of singlet oxygen in a cell. J. Phys. Chem. B, 2005, 109, 8570-8573.
93. Snyder, J. W.; Skovsen, E.; Lambert, J. D. C.; Ogilby, P. R. Subcellular, time-resolved studies of singlet oxygen in single cells. J. Amer. Chem. Soc., 2005, 127, 14558-14559.
94. Georgiou, G. N.; Ahmet, M. T.; Houlton, A.; Silver, J.; Cherry, R. J. Measurement of the rate of uptake and subcellular localization of porphyrins in cells using fluorescence digital imaging microscopy. Photochem. Photobiol., 1994, 59, 419-422.
95. Fiel, R. J. Porphyrin-nucleic acid interactions: A review. J. Biomol. Struct. Dyn., 1989, 6, 1259-1275.
96. Borissevitch, I. E.; Gandini, S. C. M. Photophysical studies of excited-state characteristics of meso-tetrakis(4-N-methylpyridiniumyl) porphyrin bound to DNA. J. Photochem. Photobiol. B, 1998, 43, 112-120.
97. Gandini, S. C. M.; Yushmanov, V. E.; Perussi, J. R.; Tabak, M.; Borissevitch, I. E. Binding of the Mn(III) complex of mesotetrakis(4-N-methyl-pyridiniumyl) porphyrin to DNA. Effect of ionic strength. J. Inorg. Biochem., 1999, 73, 35-40.
98. Romera, C.; Sabater, L.; Garofalo, A.; M. Dixon, I.; Pratviel, G. Interaction of cationic nickel and manganese porphyrins with the minor groove of DNA. Inorg. Chem., 2010, 49, 8558-8567.
99. Batinic-Haberle, I.; Benov, L.; Spasojevic, I.; Fridovich, I. The ortho effect makes manganese(III) meso-tetrakis(Nmethylpyridinium-2-yl)porphyrin a powerful and potentially useful superoxide dismutase mimic. J. Biol. Chem., 1998, 273, 24521-24528.
100. Tada-Oikawa, S.; Oikawa, S.; Hirayama, J.; Hirakawa, K.; Kawanishi, S. Dna damage and apoptosis induced by photosensitization of 5,10,15,20-tetrakis (n-methyl-4-pyridyl)-21h,23h-porphyrin via singlet oxygen generation. Photochem. Photobiol., 2009, 85, 1391-1399.
101. Muñoz-Pinedo, C.; Ruiz-Ruiz, C.; Ruiz de Almodovar, C.; Palacios, C.; Lopez-Rivas, A. Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing. J. Biol. Chem., 2003, 278, 12759-12768.
102. Izyumov, D. S.; Avetisyan, A. V.; Pletjushkina, O. Y.; Sakharov, D. V.; Wirtz, K. W.; Chernyak, B. V.; Skulachev, V. P. "Wages of fear": transient threefold decrease in intracellular ATP level imposes apoptosis. Biochim. Biophys. Acta, 2004, 1658, 141-147.
103. Boros, L. G.; Lee, P. W.; Brandes, J. L.; Cascante, M.; Muscarella, P.; Schirmer, W. J.; Melvin, W. S.; Ellison, E. C. Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism? Med. Hypotheses, 1998, 50, 55-59.
104. Coy, J. F.; Dressler, D.; Wilde, J.; Schubert, P. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin. Lab., 2005, 51, 257-273.
105. Schwartz, A. G.; Pashko, L. L. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J. Cell. Biochem. Suppl., 1995, 22, 210-217.
106. Pelicano, H.; Martin, D. S.; Xu, R. H.; Huang, P. Glycolysis inhibition for anticancer treatment. Oncogene, 2006, 25, 4633-4646.
107. Rais, B.; Comin, B.; Puigjaner, J.; Brandes, J. L.; Creppy, E.; Saboureau, D.; Ennamany, R.; Lee, W. N.; Boros, L. G.; Cascante, M. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett., 1999, 456, 113-118.
108. Uzdensky, A. B. Signal transduction and photodynamic therapy. Curr. Sig. Trans. Ther., 2008, 3, 55-74.
109. Kessel, D. Death pathways associated with photodynamic therapy. Med. Laser Appl., 2006, 21, 219-224.
110. Kessel, D.; Oleinick, N. L. Photodynamic therapy and cell death pathways. Meth. Molec. Biol. (Clifton, N.J.), 2010, 635, 35-46.
111. Bhowmick, R.; Girotti, A. W. Signaling events in apoptotic photokilling of 5-aminolevulinic acid-treated tumor cells: Inhibitory effects of nitric oxide. Free Radic. Biol. Med., 2009, 47, 731-740.
112. Höckel, M.; Vaupel, P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst., 2001, 93, 266-276.